^
Association details:
| Biomarker: | EGFR mutation + TP53 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Roles of p53 and AXL Expressions on the Efficacy of ICI-Based Therapy in Patients with EGFR Mutated Lung Cancer after Osimertinib
Published date:
08/08/2023
Excerpt:
A total of 36 patients with advanced or recurrent EGFR-mutant NSCLC were analyzed. In multivariate analysis, p53 expression in tumors was an independent predictor of PFS after ICI-based therapy (p = 0.002).
